Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type (PLoS Pathogens (2020) 15:12 (E1008121) DOI: 10.1371/journal.ppat.1008121)

0Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Dr. Giacomo Gorini is not included in the author byline. He should be listed as the seventeenth author and affiliated with Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America. The contribution of this author is as follows: Methodology.

Cite

CITATION STYLE

APA

Schifanella, L., Barnett, S. W., Bissa, M., Galli, V., Doster, M. N., Vaccari, M., … Franchini, G. (2020, April 1). Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type (PLoS Pathogens (2020) 15:12 (E1008121) DOI: 10.1371/journal.ppat.1008121). PLoS Pathogens. Public Library of Science. https://doi.org/10.1371/journal.ppat.1008531

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free